ICU Medical (STU:IC7) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:IC7 ICU Medical Inc STU:IC7
80 GF Score
Price €158.00
GF Value €105.79
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is ICU Medical Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:IC7
80GF Score
ICU Medical Inc STU:IC7
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ICU Medical (STU:IC7) Overvalued in 2026?

Based on GuruFocus' analysis, ICU Medical stock appears to be overvalued. The current stock price of €158.00 is trading 49.4% above its estimated GF Value™ of €105.79. GuruFocus considers ICU Medical to be Significantly Overvalued.

Key valuation signals for STU:IC7:

  • Interest Received:
  • GF Value™: €105.79 vs. price of €158.00 (49.4% above fair value)
  • GF Score™: 80/100 with 8 warning signs

No single metric tells the full story. See the STU:IC7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ICU Medical Business Description

Other Exchanges ICUI:USA
Address 951 Calle Amanecer, San Clemente, CA, USA, 92673
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
80GF Score

Get the complete analysis for STU:IC7

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€158.00
Price
€105.79
GF Value